• Adial Pharmaceuticals posted net loss of USD 2.02 million, narrowing from USD 2.23 million year earlier.
• Operating loss improved to USD 2 million as operating expenses fell to USD 2 million, led by research and development expense dropping 42% to USD 433,000.
• General and administrative costs rose 3% to USD 1.57 million, driven by higher business development spending.
• Cash and cash equivalents totaled USD 4.6 million at March 31, 2026; management said cash on hand funds operations into second half of 2026 and flagged substantial doubt about ability to continue as a going concern without additional funding.
• Entered collaboration framework with Molteni Farmaceutici for proposed exclusive European commercialization of AD04, with potential aggregate value from milestones and royalties estimated at nearly USD 60 million; sold 181,230 shares via ATM for net proceeds of about USD 315,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-053907), on May 08, 2026, and is solely responsible for the information contained therein.